![How the Johnson and Johnson vaccine is different from the others: Dosage, efficacy, protection, technology - ABC11 Raleigh-Durham How the Johnson and Johnson vaccine is different from the others: Dosage, efficacy, protection, technology - ABC11 Raleigh-Durham](https://cdn.abcotvs.com/dip/images/10376742_022721-wls-jj-vaccine-img.jpg)
How the Johnson and Johnson vaccine is different from the others: Dosage, efficacy, protection, technology - ABC11 Raleigh-Durham
![U.S. To Review J&J Shot After 6 Blood Clot Cases Reported Out Of Nearly 7M Doses : Coronavirus Updates : NPR U.S. To Review J&J Shot After 6 Blood Clot Cases Reported Out Of Nearly 7M Doses : Coronavirus Updates : NPR](https://media.npr.org/assets/img/2021/04/13/ap21065661043422-c7d09feb7a545d0f9a49a14bcd59e3d7043d055d.jpg)
U.S. To Review J&J Shot After 6 Blood Clot Cases Reported Out Of Nearly 7M Doses : Coronavirus Updates : NPR
![New Johnson & Johnson data shows second shot boosts antibodies and protection against COVID-19 – but one dose is still strong against delta variant New Johnson & Johnson data shows second shot boosts antibodies and protection against COVID-19 – but one dose is still strong against delta variant](https://images.theconversation.com/files/423187/original/file-20210924-3841-key6pj.jpg?ixlib=rb-1.1.0&rect=89%2C131%2C4527%2C2941&q=20&auto=format&w=320&fit=clip&dpr=2&usm=12&cs=strip)
New Johnson & Johnson data shows second shot boosts antibodies and protection against COVID-19 – but one dose is still strong against delta variant
![COVID-19 Vaccine: Johnson & Johnson Trial Paused Amid 'Unexplained Illness' : Coronavirus Updates : NPR COVID-19 Vaccine: Johnson & Johnson Trial Paused Amid 'Unexplained Illness' : Coronavirus Updates : NPR](https://media.npr.org/assets/img/2020/10/13/ap_20287085268903-6ca24dccdd8bf0f4275235c62a8d123271d908eb.jpg)
COVID-19 Vaccine: Johnson & Johnson Trial Paused Amid 'Unexplained Illness' : Coronavirus Updates : NPR
![Janssen Announces Exclusive, Worldwide License Agreement With Arrowhead Pharmaceuticals to Develop and Commercialize a New Treatment for Chronic Hepatitis B Viral Infection Janssen Announces Exclusive, Worldwide License Agreement With Arrowhead Pharmaceuticals to Develop and Commercialize a New Treatment for Chronic Hepatitis B Viral Infection](https://mma.prnewswire.com/media/722128/Janssen_Johnson_and_Johnson_logo.jpg?p=facebook)
Janssen Announces Exclusive, Worldwide License Agreement With Arrowhead Pharmaceuticals to Develop and Commercialize a New Treatment for Chronic Hepatitis B Viral Infection
![Janssen Showcases Phase 2 Nipocalimab (M281) Data in Adults with Generalized Myasthenia Gravis (gMG) at the 2021 American Academy of Neurology Virtual Meeting Janssen Showcases Phase 2 Nipocalimab (M281) Data in Adults with Generalized Myasthenia Gravis (gMG) at the 2021 American Academy of Neurology Virtual Meeting](https://mma.prnewswire.com/media/773032/Janssen_Pharmaceutical_Companies_of_Johnson_and_Johnson_Logo.jpg?p=twitter)
Janssen Showcases Phase 2 Nipocalimab (M281) Data in Adults with Generalized Myasthenia Gravis (gMG) at the 2021 American Academy of Neurology Virtual Meeting
![So you got the J&J vaccine? Here's what you should know about the delta variant, boosters, and more | AAMC So you got the J&J vaccine? Here's what you should know about the delta variant, boosters, and more | AAMC](https://www.aamc.org/sites/default/files/JAndJVaccineBoxes-1200x666.jpg)